6Xing M,Westra WH,Tufano RP,et al.BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.J Clin Endocrinol Metab,2005,90:6373-6379.
7Lee X,Gao M,Ji Y,et al.Analysis of differential BRAF (V600E) mutational status in high aggressive papillary thyroid microcarcinoma.Ann Surg Oncol,2009,2:240-245.
3Hundahl SA, Fleming ID, Fremgen AM, et al. A national cance data base report on 53 856 eases of thyroid carcinoma treated in the U. S, 1985-1995. Cancer,1998,83: 2638-2648.
4Peyssonnaux C, Eychene A. The RAF/MEK/ERK pathway: new concepts of activation. Biol Cell ,2001,93: 53-62.
5Duesbery NS, Webb CP, Vande Woude GF. MEK wars, a new front in the battle against cancer. Nat Med,1999,5 : 736-742.
6Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules, Clin Can Res,2004,10 : 2761-2765.
7Xing MZ, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab,2004,89 : 2867-2872.
8Davies H, Bignell GR, Cox C,et al. Mutations of the BRAF gene in human cancer, Nature,2002,417-949.
9Xing MZ. BRAF mutation in thyroid cancer. Endocrine-Related Cancer ,2005,12 : 245-262.
10Namba H,Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab,2003,88 :4393-4397.
2Ikawa S, Fukui M, Ueyama Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement[ J]. Mol Cell Biol, 1988, 8(6) :2651-2654.
3Kamata T, Pritchard C. Mechanisms of aneuploidy induction by RAS and RAF oncogenes[ J]. Am J Cancer Res, 2011, 1(7) : 955-971.
4Cutler RE Jr, Stephens RM, Saracino MR, et al. Autoregulation of the Raf-1 serine/threonine kinase[J]. Proc Natl Acad Sci U S A, 1998, 95(16) :9214-9219.
5Davies H, BigneU GR, Cox C, et al. Mutations of the BRAF gene in human cancer [ J ]. Nature, 2002, 417 (6892) : 949-954.
6Millington GW. Mutations of the BRAF gene in human cancer, by Davies et al. ( Nature 2002, 417: 949-54) [ J 1. Clin Exp Dermatol, 2013, 38(2):222-223.
7Abouyabis AN, Shenoy P J, Lechowicz M J, et al. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States [ J ]. Leuk Lymphoma, 2008, 49 ( 11 ) : 2099-2107.
8Aoki R, Kambe K, Sugita Y, et al. Dismb ution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006[ J]. Pathol Int, 2008, 58(3) : 174-182.
9Lee MY, Tan TD, Feng AC, et al. Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution [ J ]. Am J Hematol, 2006, 81 ( 8 ) : 568-575.
10Au WY, Ma SY, Chim CS, et al. Clinicopathologie features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years[ J ]. Ann Oncol, 2005, 16(2) :206-214.
